ArticleSurgery today2012
Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
Article in Surgery today, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1.International journal of clinical oncology · 2024Article
- Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA.International journal of clinical oncology · 2020Article
- Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.International journal of clinical oncology · 2020Article
- Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.Disease markers · 2019Article
- Multi-panel assay of serum autoantibodies in colorectal cancer.International journal of clinical oncology · 2018Article
- Unusually high levels of serum p53 antibody in recurrent gastric cancer.Clinical journal of gastroenterology · 2017Article
- Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer.Molecular and clinical oncology · 2017Article
- The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.Surgery today · 2017Article
- Zoledronic Acid Regulates Autophagy and Induces Apoptosis in Colon Cancer Cell Line CT26.BioMed research international · 2017Article
- Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer.Clinical journal of gastroenterology · 2016Article
- Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.Surgery today · 2014Article
- Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.Surgery today · 2014Article
- Cancer Antigens (CEA and CA 19-9) as Markers of Advanced Stage of Colorectal Carcinoma.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2013Article
- Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC).Experimental hematology & oncology · 2013Article
- The application of current diagnostic protocols of patients with colon cancer in preparation for therapy.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe reevaluated the serum p53 antibody (S-p53Ab) ELISA kit, which was approved as a tumor marker of colon cancer in the Japanese Health Insurance System in 2007.
methodsS-p53Ab was measured as a tumor marker in 154 colorectal cancer patients, and the results were categorized by clinical and pathological variables. We then compared the positive frequency of S-p53Ab, carcinoembryonic antigen (CEA), and carbohydrate 19-9 (CA19-9).
resultsS-p53Ab was positive in 33.1% of the colorectal cancer patients. The positive rate was significantly higher in patients with lymph nodes metastasis (P = 0.025) and lymphatic invasion (P = 0.023). In patients with stage I colorectal cancer, the positive rate of S-p53Ab (23.7%) was significantly higher than that of CEA (5.3%) or CA19-9 (7.9%).
conclusionThe approved kit for S-p53Ab testing was found to be an effective tumor marker of colorectal cancer. The positive rate of S-p53Ab was significantly higher in patients with cancer involvement of the lymphoid tissues. The positive rate of S-p53Ab was higher than that of CEA and CA19-9 in patients with stage I colorectal cancer, suggesting that the S-p53Ab is a useful tumor marker for patients with early-stage disease.
Indexed as
Identifiers
22075664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.